CJC-1295 DAC: Human Research, Hormone Effects and Safety Limits
CJC-1295 DAC is a long-acting growth hormone-releasing hormone analogue investigated for sustained stimulation of GH and IGF-I. The central human findings concern hormone concentrations and secretion patterns. They should not be presented as demonstrated improvements in muscle strength, recovery or longevity. Teichman trial abstract
If you are researching benefits, start by separating the exact preparation from the outcome being advertised. This profile concerns the long-acting material studied under the CJC-1295 name. Keep the DAC designation visible when comparing it with a product described as “no DAC,” and do not transfer results between formulations without checking identity.
What does the DAC distinction mean for the evidence?
The early development literature investigated albumin-linked growth hormone-releasing factor analogues and identified CJC-1295 as a long-lasting analogue in rat research. That work addresses a design and pharmacology question, not a clinical claim about better physical performance. Jetté et al., original indexed research record
For a practical identity check, record the complete name used by the study, the formulation description and any information about the salt form. Compare those details with the material under discussion before comparing half-life or effects. A familiar short name should not do the work of a documented identity match.
FDA’s December 2024 advisory-committee materials specifically identified inconsistent naming and missing characterization information among CJC-1295-related bulk substances. They also noted that the salt forms were not specified in the clinical references discussed. FDA review slides
Our recommendation is to label an unresolved match as unresolved. The peptide naming guide provides a detailed workflow, and the CJC-1295 no-DAC profile is a separate starting point for that formulation question.
What did the controlled human trials find?
Teichman and colleagues conducted two randomized, double-blind, placebo-controlled studies lasting 28 and 49 days in healthy adults aged 21 to 61. After a single administration, the abstract reports mean GH increases of two- to ten-fold lasting at least six days and mean IGF-I increases of 1.5- to three-fold for nine to eleven days. The estimated CJC-1295 half-life was 5.8 to 8.1 days. Original abstract
The study’s hormone measurements are relevant to prolonged biological activity. Keep the duration and preparation attached to the finding. Do not convert the half-life estimate into a personal administration interval, or treat a larger hormone multiplier as a quantified benefit in another outcome.
For example, if your question is improved strength, locate the actual strength measure and comparison before drawing a conclusion. A hormone result can be a useful research finding while leaving that practical question unanswered.
What does “preserved pulsatility” establish?
Ionescu and Frohman examined overnight GH patterns in healthy men aged 20 to 40, using repeated sampling before and one week after CJC-1295. They reported unchanged pulse frequency and magnitude alongside a 7.5-fold increase in trough GH, a 46% increase in mean GH and a 45% increase in IGF-I. Original abstract
Preserve the measurement labels when summarizing this result. Trough, mean and pulse characteristics describe different features of the observed pattern. Avoid replacing the entire result with a phrase such as “normal hormone release” that conceals what changed.
This study gives a more detailed account than a single hormone measurement. It does not supply a measured recovery benefit simply because the secretion remained pulsatile. For a broader explanation of that distinction, see hormone levels versus physical benefits.
An evidence map for common claims
Use this original comparison framework to match a proposed benefit with the evidence you would need. It is a reading aid, not a treatment decision tool.
| Claim you encounter | What to verify before repeating it |
|---|---|
| “Long acting” | Exact preparation, measured pharmacokinetics and observation period |
| “Raises GH or IGF-I” | Hormone measure, baseline, comparator, timing and uncertainty |
| “Builds muscle” | A direct muscle outcome in a relevant trial, not the hormone result alone |
| “Improves recovery” | A defined recovery outcome and meaningful comparison |
| “Treats GH deficiency” | Evidence in that diagnosed population and the applicable clinical context |
| “Safe for ongoing use” | Adequate safety observations for the route, population and duration claimed |
When a source answers only the first two rows, keep your summary at that level. Do not fill the remaining rows by combining separate studies of different interventions. A chain of plausible connections is a hypothesis to investigate, not a completed experiment.
Healthy-volunteer findings and GH deficiency
In its December 2024 review, FDA concluded that the information discussed did not support effectiveness of subcutaneous CJC-1295-related bulk substances for treating growth hormone deficiency. The review also highlighted unknown long-term safety and a lack of pediatric safety data. FDA advisory-committee materials
Treat that as a dated assessment of the reviewed evidence. It should not be rewritten as a broad legal statement about every jurisdiction or a substitute for checking subsequent regulatory decisions.
For an individual concerned about GH deficiency, the useful next step is a clinical assessment, not selection of an online peptide protocol. Bring the original evidence and the exact product question to a qualified clinician. This profile does not identify who should receive treatment or provide diagnostic thresholds.
Safety findings and unresolved risks
FDA’s safety-risk page flags potential immunogenicity and characterization concerns for compounded CJC-1295, and reports serious adverse events associated with it, including increased heart rate and systemic vasodilatory reactions. The agency describes the clinical data as limited. FDA safety information, checked September 2026
The Teichman abstract reports no serious adverse reactions in its two trials. Keep that bounded observation separate from a general safety guarantee. Trial abstract
In your research notes, record both the favorable short-study observation and the later safety assessment. Ask about route, repeated exposure, follow-up and the population studied. Do not infer that absence of a reported event in a small research program establishes absence of risk elsewhere.
Avoid listing speculative symptoms as though they were measured frequencies. If an event is mentioned without a denominator or clear causality assessment, retain those limitations. The point of the safety section is to clarify the evidence, not to produce an impressive-looking list of unsupported risks.
How to read a CJC-1295 product document
Begin with identity. Ask which full compound name, lot and analytical material the document describes. Then separate identity evidence from purity, amount and other quality questions. Our COA and purity explainer walks through those distinctions.
Do not use a purity percentage to bridge a clinical evidence gap. A document about a laboratory sample does not replace the need for a trial addressing the benefit claimed. Conversely, a published trial does not establish the composition of a particular supplier’s vial.
For a blend, record every ingredient and look for research on the combination itself. Use the blend evidence guide before transferring a CJC-1295 finding to an ipamorelin mixture or another multi-ingredient preparation.
Questions worth taking back to the source
Before accepting a benefits summary, ask the author to point to the relevant section of the original paper:
- Which CJC-1295 preparation was administered?
- Were participants healthy volunteers or people with a diagnosed condition?
- Which outcomes were hormone measurements, and which were direct physical outcomes?
- How were the comparison and uncertainty reported?
- What safety observations were collected, and for how long?
- What remains untested for the specific benefit being discussed?
Write a short conclusion from those answers rather than beginning with a desired result. If a key detail is unavailable, say “not verified in the material reviewed.” That is more informative than treating missing information as favorable evidence.
Frequently asked questions
Is DAC evidence interchangeable with no-DAC evidence?
Do not assume interchangeability. Match the actual material and study description first, including the formulation details available in the report. Use separate evidence records when the identity differs or remains uncertain.
Does a longer half-life mean a better result?
Do not rank benefits from half-life alone. Request the direct outcome that matters to the claim, alongside the safety evidence. A duration measurement cannot answer every clinical question.
Does this profile provide a CJC-1295 dosing schedule?
No. Trial administration details belong to a specific research design. This profile explains the findings and their limits and does not convert them into a self-use, escalation or combination schedule.
Sources and review scope
This is a selected-source research profile. Original human abstracts, an indexed development-study record and selected FDA materials were checked. Full clinical reports and all supplementary analyses were not comprehensively appraised. It is not a systematic review.
- Teichman et al., 2006: sustained GH and IGF-I responses
- Ionescu and Frohman, 2006: GH pulsatility
- Jetté et al., 2005: albumin-linked analogue research
- FDA, December 2024: advisory-committee review materials
- FDA: bulk-substance safety concerns
Confidence tags describe the reported statements, not certification of a product or personal benefit.